Works matching IS 15391604 AND DT 2022 AND VI 21 AND IP 2

Results: 16

A dose‐finding design for dual‐agent trials with patient‐specific doses for one agent with application to an opiate detoxification trial.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 476, doi. 10.1002/pst.2181

By:

Mozgunov, Pavel;
Cro, Suzie;
Lingford‐Hughes, Anne;
Paterson, Louise M.;
Jaki, Thomas

Publication type:

Article

Obituary: Sir David Cox.

Published in:: 2022
Publication type:: Obituary

TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 496, doi. 10.1002/pst.2182

By:

Takeda, Kentaro;
Xia, Qing;
Liu, Shufang;
Rong, Alan

Publication type:

Article

Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequence.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 460, doi. 10.1002/pst.2180

By:

Rothwell, Joanne C.;
Julious, Steven A.;
Cooper, Cindy L.

Publication type:

Article

Improving the assessment of the probability of success in late stage drug development.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 439, doi. 10.1002/pst.2179

By:

Hampson, Lisa V.;
Bornkamp, Björn;
Holzhauer, Björn;
Kahn, Joseph;
Lange, Markus R.;
Luo, Wen‐Lin;
Cioppa, Giovanni Della;
Stott, Kelvin;
Ballerstedt, Steffen

Publication type:

Article

The power prior with multiple historical controls for the linear regression model.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 418, doi. 10.1002/pst.2178

By:

Banbeta, Akalu;
Lesaffre, Emmanuel;
van Rosmalen, Joost

Publication type:

Article

Bivariate Bayesian hypothesis testing with missing data in components.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 395, doi. 10.1002/pst.2177

By:

Xu, Zhixing;
Quan, Hui

Publication type:

Article

A note on point estimation and interval estimation of the relative treatment effect under a simple crossover design.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 386, doi. 10.1002/pst.2176

By:

Lin, Chii‐Dean;
Lui, Kung‐Jong

Publication type:

Article

Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 372, doi. 10.1002/pst.2175

By:

Waterhouse, Brian;
Hartford, Alan;
Mukhopadhyay, Saurabh;
Ferguson, Ryan;
Hendrickson, Barbara A.

Publication type:

Article

Practical and robust test for comparing binomial proportions in the randomized phase II setting.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 361, doi. 10.1002/pst.2174

By:

Attwood, Kristopher;
Park, Soyun;
Hutson, Alan D.

Publication type:

Article

Statistical detection of synergy: New methods and a comparative study.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 345, doi. 10.1002/pst.2173

By:

Thas, Olivier;
Tourny, Annelies;
Verbist, Bie;
Hawinkel, Stijn;
Nazarov, Maxim;
Mutambanengwe, Kathy;
Bijnens, Luc

Publication type:

Article

Ensuring exchangeability in data‐based priors for a Bayesian analysis of clinical trials.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 327, doi. 10.1002/pst.2172

By:

Lin, Junjing;
Gamalo‐Siebers, Margaret;
Tiwari, Ram

Publication type:

Article

Extending the two‐stage single arm phase II clinical trial design to the delayed response scenario.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 317, doi. 10.1002/pst.2171

By:

Chen, Bo;
Zhao, Xing;
Zhang, Juying

Publication type:

Article

A note on confidence intervals for the restricted mean survival time based on transformations in small sample size.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 309, doi. 10.1002/pst.2170

By:

Hashimoto, Hiroya;
Kada, Akiko

Publication type:

Article

Semi‐parametric accelerated failure‐time model: A useful alternative to the proportional‐hazards model in cancer clinical trials.

Published in:: Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 292, doi. 10.1002/pst.2169
Publication type:: Article

Issue Information.

Published in:: Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 289, doi. 10.1002/pst.2134
Publication type:: Article